Kura Oncology (KURA) director receives option grant for 35,000 shares at $8.77

Rhea-AI Filing Summary

Kura Oncology director Thomas Malley received a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was reported as a grant or award, not an open-market purchase or sale.

The option vests in full on the one-year anniversary of the grant date and expires on June 3, 2036 if not exercised. Following this award, Malley’s reported derivative holdings in this option total 35,000 underlying shares, reflecting a compensation-related equity incentive rather than a discretionary trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Malley Thomas

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	35,000	$0.00	--

Holdings After Transaction: Option to purchase common stock — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 shares Exercise price: $8.77 per share Expiration date: June 3, 2036 +1 more

4 metrics

Option grant size 35,000 shares Options to purchase common stock granted to Thomas Malley

Exercise price $8.77 per share Conversion or exercise price of the option

Expiration date June 3, 2036 Option expiration if not exercised

Shares following transaction 35,000 shares Total underlying shares in this option after grant

Key Terms

Option to purchase common stock, Grant, award, or other acquisition, exercise price, vests in full

4 terms

Option to purchase common stock financial

"security_title: Option to purchase common stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 8.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"This option vests in full on the one year anniversary"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malley Thomas

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$8.77	06/04/2026		A		35,000		(1)	06/03/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

	/s/ Teresa Bair, Attorney-in-fact for Thomas Malley	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Thomas Malley report in his latest Form 4 for KURA?

Thomas Malley reported receiving an option to purchase 35,000 shares of Kura Oncology common stock. The award is a compensation-related grant, not an open-market trade, and gives him the right to buy shares at a fixed exercise price of $8.77.

Is the Thomas Malley Form 4 transaction a buy or sell of KURA stock?

The Form 4 shows an acquisition of a stock option award, not a buy or sell in the open market. The transaction is coded as a grant or award acquisition and provides future purchase rights at $8.77 per share.

What are the key terms of Thomas Malley’s KURA stock option grant?

The grant covers options on 35,000 Kura Oncology common shares with an $8.77 exercise price. The option vests in full one year after the grant date and will expire on June 3, 2036 if it is not exercised by then.

When do Thomas Malley’s KURA options from this Form 4 vest?

The filing states the option vests in full on the one-year anniversary of the grant date. This means Malley must remain eligible until that one-year mark before he can exercise the entire 35,000-share award.

How many KURA underlying shares does Thomas Malley hold from this option grant?

After this transaction, Malley’s reported holdings in this option correspond to 35,000 underlying Kura Oncology common shares. This entire amount comes from the new grant, as reflected in the total shares following the transaction field.